Immunic, inc. reports second quarter 2023 financial results and provides corporate update

– preclinical data published in the journal of medicinal chemistry identifies vidofludimus calcium as a potent nurr1 activator, reinforcing neuroprotective potential in multiple sclerosis – – positive results from phase 1b clinical trial of imu-856 in celiac disease provide proof-of-concept for a new therapeutic approach to treat gastrointestinal diseases by promoting regeneration of bowel architecture – – interim results from phase 2 calliper trial of vidofludimus calcium in progressive multiple sclerosis expected in the fall of 2023 – – $77.3 million in cash, cash equivalents and investments expected to fund immunic into the fourth quarter of 2024 – – webcast to be held today, august 3, 2023, at 8:00 am et – new york , aug. 3, 2023 /prnewswire/ -- immunic, inc.  (nasdaq: imux), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced financial results for the second quarter ended june 30, 2023, and provided a corporate update. "during the second quarter, we reported important clinical and preclinical data from our two, lead pipeline programs, including the most advanced drug candidate, vidofludimus calcium (imu-838), as well as imu-856," stated daniel vitt, ph.d.
IMUX Ratings Summary
IMUX Quant Ranking